Peptide Research
MOTS-c and Mitochondrial-Derived Peptides in Research
⚠ FOR LABORATORY RESEARCH AND EDUCATIONAL PURPOSES ONLY — NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Quick answer: Mitochondrial peptides — also called mitochondrial-derived peptides (MDPs) — are small peptides encoded within mitochondrial DNA rather than nuclear DNA. The best-characterised are MOTS-c and humanin. Published preclinical research examines them as signalling molecules involved in cellular energy metabolism, stress-response pathways, and aging biology. This article summarises that literature for qualified researchers; all compounds discussed are supplied strictly as research materials.
What Are Mitochondrial-Derived Peptides?
Mitochondria carry their own genome, separate from nuclear DNA. Researchers have identified several short open reading frames within that genome which encode small bioactive peptides — the mitochondrial-derived peptides. Because these peptides appear to signal between the mitochondrial and nuclear genomes, they occupy a distinct niche in cell-signalling research compared with hormonally active peptides.
Declining mitochondrial efficiency and increased reactive oxygen species production are widely described in the aging-biology literature as central features of cellular aging.1 Consequently, MDPs have become an active area of preclinical investigation.2
Humanin: A Cytoprotective Signalling Peptide
Japanese researchers first identified humanin in 2001 in brain tissue that showed resistance to Alzheimer’s pathology. It is a 24-amino-acid peptide encoded by mitochondrial DNA, and published work characterises it as a cellular stress signal associated with apoptosis regulation.3
Research published in the cardiovascular and metabolic literature reports that circulating humanin concentrations decline with age in observational cohorts, and that higher measured levels correlate with cardiovascular and cognitive markers.4 In rodent models, humanin administration has been reported to affect insulin sensitivity, inflammatory markers, and atherosclerotic progression.5 Notably, these findings remain preclinical or observational — they do not establish therapeutic effects in humans.
MOTS-c: AMPK Signalling and the “Exercise Mimetic” Question
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide identified in 2015 by Changhan David Lee and colleagues at the University of Southern California.6 It carries CAS number 1627580-64-6 and is supplied for research as a lyophilized powder.
A frequently cited study in Cell Metabolism reported that MOTS-c activates AMPK — the same metabolic sensor implicated in exercise response. In aged mouse models, investigators observed changes in physical performance, insulin sensitivity, and adiposity following MOTS-c administration.7 Subsequent work reported that endogenous MOTS-c expression declines with age and rises following exercise protocols, which is why the literature often describes it as an “exercise-induced” mitochondrial peptide.
Because MOTS-c also translocates to the nucleus, researchers additionally study it in gene-expression and epigenetic contexts — a mechanism distinct from receptor-mediated peptide signalling. Qualified laboratories investigating these pathways can source research-grade MOTS-c with a batch-specific Certificate of Analysis.
SS-31 (Elamipretide): The Furthest Along in Clinical Development
SS-31 — also referred to as elamipretide, MTP-131, or Bendavia — differs from humanin and MOTS-c in one important respect: scientists engineered it synthetically rather than finding it encoded in the mitochondrial genome. This four-amino-acid peptide was designed to associate with the inner mitochondrial membrane and stabilise cardiolipin, a phospholipid required for efficient electron transport.8
Among the compounds discussed here, SS-31 has progressed furthest through formal clinical development, with Phase 2 and Phase 3 programmes conducted in heart failure, Barth syndrome, and age-related macular degeneration, and an FDA Orphan Drug Designation granted for Barth syndrome in 2023.9,10 Not all trials met their primary endpoints. Laboratories working in this area can review our SS-31 research peptide specifications and published COA.
Comparing the Major Mitochondrial Peptides
| Peptide | Size | Primary Research Focus | Development Stage |
|---|---|---|---|
| Humanin | 24 amino acids | Cell-survival signalling | Preclinical |
| MOTS-c | 16 amino acids | Metabolic and AMPK signalling | Preclinical |
| SS-31 (elamipretide) | 4 amino acids | Mitochondrial membrane stabilisation | Phase 2/3 trials |
| SHLP 1–6 | 24–38 amino acids | Various cytoprotective pathways | Early preclinical |
Why Purity Matters in Mitochondrial Peptide Research
Mitochondrial signalling assays are sensitive to contaminants. Specifically, residual endotoxin can trigger inflammatory signalling that confounds metabolic readouts, while synthesis-related impurity peptides introduce variability across replicates. For this reason, laboratories working with MDPs generally require documented HPLC purity, mass-spectrometry identity confirmation, and LAL endotoxin testing before use.
LiveWell manufactures its research peptides in our own cGMP facility in Dallas, Texas — we are the manufacturer, not a reseller — and we publish batch-specific documentation on our COA page rather than supplying it on request only.
Frequently Asked Questions
What are mitochondrial peptides?
Mitochondrial peptides, or mitochondrial-derived peptides (MDPs), are small peptides encoded within mitochondrial DNA. Humanin, MOTS-c, and the SHLP family are the main examples studied in cellular energy and aging research. SS-31 (elamipretide) is a synthetic peptide studied in the same field.
What does MOTS-c do in research models?
Published studies report that MOTS-c activates AMPK signalling and influences glucose utilisation and insulin sensitivity in cell and rodent models. Because exercise activates the same pathway, the literature frequently characterises it as an exercise-induced mitochondrial peptide. Human evidence remains limited.
What is the difference between MOTS-c and SS-31?
MOTS-c is encoded within mitochondrial DNA and studied primarily for AMPK-linked metabolic signalling. By contrast, SS-31 (elamipretide) is a synthetic four-amino-acid peptide engineered to stabilise cardiolipin in the inner mitochondrial membrane, and it has progressed further through clinical trials.
Are mitochondrial peptides approved therapies?
No. Most mitochondrial peptides remain in preclinical or early clinical research. SS-31 has advanced furthest, but no mitochondrial peptide is approved as an anti-aging or metabolic therapy. All material supplied by LiveWell is for laboratory research use only.
How should mitochondrial peptides be stored for research use?
Store lyophilized vials refrigerated at 2–8°C, protected from light and heat. Reconstitute with bacteriostatic water; reconstituted material has a considerably shorter storage window. Follow your laboratory’s standard peptide handling protocol.
Related Research
Continue the series: Growth Hormone Peptides · Peptides in Sleep and Stress Research · Why Did Peptide Sciences Shut Down?
Research compounds: MOTS-c · SS-31 · NAD+ · All research vials · Certificates of Analysis
External context: National Institute on Aging · PubMed
References
- López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243–278.
- Kim SJ, et al. Mitochondrial-derived peptides in aging and age-related diseases. GeroScience. 2021;43:1113–1121.
- Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Aβ. PNAS. 2001;98(11):6336–6341.
- Cobb LJ, et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis. J Am Heart Assoc. 2016;5(10):e003646.
- Muzumdar RH, et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One. 2009;4(7):e6334.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443–454.
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline. Nature Communications. 2021;12:470.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–2050.
- Stealth BioTherapeutics. Elamipretide clinical development pipeline. 2025.
- U.S. FDA. Orphan Drug Designation: elamipretide (Barth syndrome). 2023.
- Merry TL, et al. Mitochondrial-derived peptides in energy metabolism. Molecular Metabolism. 2020;32:1–14.
For research and educational purposes only. This article summarises findings from published preclinical and observational literature as a scientific reference for qualified researchers. It does not describe effects in humans, is not medical or health advice, and no compound discussed is approved to diagnose, treat, cure, mitigate, or prevent any disease. All LiveWell products are supplied strictly for in-vitro laboratory research and are not for human or animal consumption.